Conference Coverage

Lidocaine Effective Against Pediatric Migraine


 

FROM AHS 2024

Important Research in an Understudied Population

Laine Greene, MD, who moderated the session, was asked for comment. “I think it’s an important study. Occipital nerve blocks have been used for a long period of time in management of migraine and other headache disorders. The quality of the evidence has always been brought into question, especially from payers, but also a very important aspect to this is that a lot of clinical trials over time have not specifically been done in children or adolescents, so any work that is done in that age category is significantly helpful to advancing therapeutics,” said Dr. Greene, associate professor of neurology at Mayo Clinic Arizona.

Dr. Szperka has consulted for AbbVie and Teva, and serves on data safety and monitoring boards for Eli Lilly and Upsher-Smith. She has been a principal investigator in trials sponsored by Abbvie, Amgen, Biohaven/Pfizer, Teva, and Theranica. Dr. Greene has no relevant financial disclosures.

Pages

Recommended Reading

How a concussion led a former football player/WWE star to a pioneering neuroscience career
MDedge Pediatrics
‘Quick, affordable’ test helps predict CGRP response for migraine
MDedge Pediatrics
Migraine after concussion linked to worse outcomes
MDedge Pediatrics
Migraine device expands treatment possibilities
MDedge Pediatrics
Are migraine preventives underused in young adults?
MDedge Pediatrics
Adolescents with migraine need smooth handoff to adult care
MDedge Pediatrics
Which migraine medications are most effective?
MDedge Pediatrics
Risk Factors for Headache in Youth Identified
MDedge Pediatrics
IV Ketamine Promising for Severe Refractory Headache in Children
MDedge Pediatrics
Lidocaine Nerve Block Effective for Severe, Refractory Migraine in Children
MDedge Pediatrics